drugset / Trial / NCT07431502

Trial to Evaluate Nonavalent HPV Vaccine as a Secondary Prevention in Patients Treated for Human Papilloma Virus Related High-grade Squamous Intraepithelial Lesions

NCT07431502

Phase 3 Not yet recruiting 984 enrolled Gustave Roussy, Cancer Campus, Grand Paris
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Randomized, placebo-controlled phase 3 trial to evaluate nonavalent HPV vaccine as a secondary prevention in patients treated for human papilloma virus related high-grade squamous intraepithelial lesions.

Timeline

Start
2026-05
Primary completion
2030-11
Completion
2030-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Gardasil Vaccine